Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Immunocore Holdings's enterprise value is $1,458.7 Mil.
Immunocore Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $13.6 Mil. Therefore, Immunocore Holdings's EV-to-EBITDA for today is 107.45.
The historical rank and industry rank for Immunocore Holdings's EV-to-EBITDA or its related term are showing as below:
IMCR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1774.08 Med: -34.96 Max: 6901.36
Current: 107.45
During the past 8 years, the highest EV-to-EBITDA of Immunocore Holdings was 6901.36. The lowest was -1774.08. And the median was -34.96.
IMCR's EV-to-EBITDA is ranked worse than 92.4% of 408
companies
in the Biotechnology industry
Industry Median: 14.13
vs IMCR: 107.45
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Immunocore Holdings's PE Ratio (TTM) for today is calculated as:
Immunocore Holdings's share price for today is $36.97.
Immunocore Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Immunocore Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immunocore Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunocore Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunocore Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Immunocore Holdings's EV-to-EBITDA falls into.
Immunocore Holdings's current Enterprise Value is $1,458.7 Mil.
Immunocore Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunocore Holdings (IMCR) has a EV-to-EBITDA of 107.45 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Immunocore Holdings. According to the industry distribution chart, Immunocore Holdings ranks #377 out of 408 companies in the Biotechnology industry, placing it in the top 92.4%.
Is Immunocore Holdings' EV-to-EBITDA too high?
Immunocore Holdings' current EV-to-EBITDA is 107.45. The Biotechnology industry median EV-to-EBITDA is 14.13. Immunocore Holdings' value of 107.45 is 660.4% above this industry median. Based on the distribution chart, Immunocore Holdings ranks #377 out of 408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunocore Holdings has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' EV-to-EBITDA compare to BCAX and SLBT?
According to the Biotechnology industry distribution chart, Immunocore Holdings ranks #377 out of 408 companies for EV-to-EBITDA. This places Immunocore Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 14.13. Immunocore Holdings' value of 107.45 is 660.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.13, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunocore Holdings's current EV-to-EBITDA of 107.45 is 660.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Immunocore Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 14.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunocore Holdings's current EV-to-EBITDA is 107.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $45.04, compared to a current price of $36.97 — trading 17.9% below its estimated fair value. The current EV-to-EBITDA is 107.45 and 660.4% above the Biotechnology industry median of 14.13. Immunocore Holdings' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current EV-to-EBITDA is 107.45 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunocore Holdings (IMCR) Overvalued in 2026?
Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued.
The current stock price of $36.97 is trading 17.9% below its estimated GF Value™ of $45.04.
GuruFocus considers Immunocore Holdings to be Modestly Undervalued.
Key valuation signals for IMCR:
EV-to-EBITDA: 107.45
GF Value™: $45.04 vs. price of $36.97 (17.9% below fair value)
Industry Position: 660.4% above the Biotechnology median (#377 of 408)
No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
80GF Score
Get the complete analysis for IMCR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMCR has been successfully added to your 
